Singapore markets closed

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
1.5500-0.0200 (-1.27%)
At close: 04:00PM EDT
1.5700 +0.02 (+1.29%)
After hours: 04:08PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.5700
Open1.5800
Bid1.5100 x 100
Ask1.6000 x 100
Day's range1.5200 - 1.6300
52-week range0.6220 - 2.5000
Volume47,010
Avg. volume203,880
Market cap25.66M
Beta (5Y monthly)2.36
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem

    --First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN, Ireland and CHICAGO, April 29, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has resubmitte

  • GlobeNewswire

    Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

    --Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today r

  • GlobeNewswire

    Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

    DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its fourth quarter and full year 2023 financial results before the open of the U.S. financial markets on Thursday, March 28, 2024. M